News

Filter

Current filters:

ZytigaJohnson & Johnson

1 to 9 of 41 results

Institute of Cancer Research study of Zytiga contradicts NICE's rejection for advanced prostate cancer

Institute of Cancer Research study of Zytiga contradicts NICE's rejection for advanced prostate cancer

05-02-2015

A study by the Institute of Cancer Research in London and the Royal Marsden NHS Foundation Trust has…

Johnson & JohnsonOncologyPharmaceuticalResearchZytiga

European prescribing trends for mCR prostate cancer

20-11-2014

Johnson & Johnson/AstraZeneca’s Zytiga (abiraterone acetate) is the clear agent of choice for second-line…

Astellas PharmaAstraZenecaBayerDendreonFranceGermanyItalyJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalProvengeSpainUKXofigoXtandiZytiga

Medivation and Astellas' Xtandi to be market-leader in prostate cancer by 2023

Medivation and Astellas' Xtandi to be market-leader in prostate cancer by 2023

31-10-2014

Xtandi (enzalutamide), produced by biopharma company Medivation and Japanese drug major Astellas Pharma…

AstellasDecision Resources GroupJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

ESMO 2014: Novartis’ Afinitor; and Janssen’s Zytiga

28-09-2014

Swiss pharma major Novartis on Saturday presented final results on overall survival (OS) from a Phase…

AfinitorJanssenJohnson & JohnsonNovartisOncologyPharmaceuticalResearchSpainZytiga

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

Delayed disease progression among the greatest unmet needs in castrate-resistant prostate cancer

29-05-2014

In addition to an improvement in median overall survival (MOS), delayed disease progression is one of…

Astellas PharmaBayerEuropeJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalUSAXofigoXtandiZytiga

Negative NICE draft guidance on Janssen’s Zytiga for prostate cancer

Negative NICE draft guidance on Janssen’s Zytiga for prostate cancer

14-05-2014

In draft guidance published this morning, the UK drugs watchdog the National Institute for Health and…

JanssenJohnson & JohnsonOncologyPharmaceuticalPricingRegulationUKZytiga

Report: New drugs needed for prostate cancer as incidents rise

Report: New drugs needed for prostate cancer as incidents rise

21-03-2014

Over half a million cases of prostate cancer will be diagnosed worldwide in 2014 leading to a demand…

EuropeJohnson & JohnsonOncologyPharmaceuticalResearchUSAXtandiZytiga

Prostate cancer market to almost double to $8 billion by 2019, says GBI

21-11-2013

The prostate cancer treatment market is forecast to increase from $4.1 billion in 2012 to $8 billion…

Active BiotechAstellas PharmaJohnson & JohnsonMarkets & MarketingOncoGenexOncologyPharmaceuticalTeva Pharmaceutical IndustriesXofigoXtandiZytiga

1 to 9 of 41 results

Back to top